Related Experiment Video
Updated: Aug 18, 2025

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
Hydroxychloroquine for treatment of COVID-19 patients: a systematic review and meta-analysis of randomized controlled
Vinícius Ynoe de Moraes1, Alexandre Rodrigues Marra1, Leandro Luongo Matos1
1Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
Insights
Hydroxychloroquine did not significantly reduce mortality in COVID-19 patients. This systematic review found no difference in mortality or serious adverse effects compared to standard care or placebo.
Area of Science:
- Infectious Diseases
- Pharmacology
- Clinical Medicine
Background:
- The COVID-19 pandemic necessitated rapid evaluation of potential treatments.
- Hydroxychloroquine was investigated for its antiviral and immunomodulatory properties.
- Evidence on its efficacy and safety in COVID-19 patients remained uncertain.
Approach:
- A systematic literature review and meta-analysis were conducted.
- Nine randomized controlled trials involving COVID-19 patients treated with hydroxychloroquine versus placebo or standard care were analyzed.
- Data on mortality and serious adverse effects were pooled using random-effects models.
Key Points:
- No significant difference in mortality rates was observed between hydroxychloroquine and control groups (16.7% vs. 18.5%).
- The rate of serious adverse effects was comparable between groups (3.7% vs. 2.9%).
- Pooled risk ratios indicated no statistically significant benefit for hydroxychloroquine.
Conclusions:
- Hydroxychloroquine is not efficacious in reducing mortality for COVID-19 patients.
- The drug demonstrated no significant safety advantage over standard care or placebo.
- Further research on hydroxychloroquine for COVID-19 is not warranted based on current evidence.
Objective:
We performed a systematic review of the literature and meta-analysis on the efficacy and safety of hydroxychloroquine to treat COVID-19 patients.
Methods:
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, and LILACS (January 2019 to March 2021) for patients aged 18 years or older, who had COVID-19 and were treated with hydroxychloroquine versus placebo or standard of care. We also searched the WHO Clinical Trials Registry for ongoing and recently completed studies, and the reference lists of selected articles and reviews for possible relevant studies, with no restrictions regarding language or publication status. Random-effects models were used to obtain pooled mean differences of treatment effect on mortality, and serious adverse effects between hydroxychloroquine and the Control Group (standard of care or placebo); heterogeneity was assessed using the I2 and the Cochran´s Q statistic.
Results:
Nine studies met the inclusion criteria and were included in the meta-analysis. There was no significant difference in mortality rate between patients treated with hydroxychloroquine compared to standard of care or placebo (16.7% versus 18.5%; pooled risk ratio 1.09; 95% confidence interval: 0.99-1.19). Also, the rate of serious adverse effects was similar between both Groups, Hydroxychloroquine and Control (3.7% versus 2.9%; pooled risk ratio 1.22; 95% confidence interval: 0.76-1.96).
Conclusion:
Hydroxychloroquine is not efficacious in reducing mortality of COVID-19 patients.
Prospero Database Registration:
(www.crd.york.ac.uk/prospero) under number CRD42020197070.
More Related Videos
04:34Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
Published on: February 17, 2023
06:29Comparing Objective Conjunctival Hyperemia Grading and the Ocular Surface Disease Index Score in Dry Eye Syndrome During COVID-19
Published on: May 25, 2022
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Rheumatic Heart Disease III: Medical Management
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Hazard Ratio
For example, in a clinical trial...